Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VRTX trades at $428.63 with a market cap of $110.81B and a P/E ratio of 25.21. VRTX moved -0.91% today. Year to date, VRTX is -3.94%; over the trailing twelve months it is -1.44%. Its 52-week range spans $362.50 to $519.88. Analyst consensus is strong buy with an average price target of $565.30. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vertex Pharmaceuticals (VRTX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. VRTX moved -0.91% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $428.63 |
| Market Cap | $110.81B |
| P/E Ratio | 25.21 |
| EPS | $17.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $519.88 |
| 52-Week Low | $362.50 |
| Volume | 1.43M |
| Avg Volume | 0 |
| Revenue (TTM) | $12.22B |
| Net Income | $4.34B |
| Gross Margin | 86.24% |
23 analysts cover VRTX: 0 strong buy, 19 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $565.30.